Bellerophon's stock tanks as in­haled drug-de­vice fails to re­deem it­self in new PhI­II af­ter pre­vi­ous flops

In the five years since Bellerophon Ther­a­peu­tics’ on­ly pro­gram, a de­vice for ad­min­is­ter­ing in­haled ni­tric ox­ide called IN­Opulse, flunked its first Phase III study, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER